Home / Blurb / Discussion Detail

FDA Approves Cemiplimab-rwlc Monotherapy for Advanced NSCLC

On February 22, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors have high PD-L1 expression (tumor proportion score ≥50%), as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK, or ROS1 aberrations. 

Read the FDA announcement.

Read the Sanofi announcement.

Posted 2/22/2021